Puma provided an update on its plan for Nerlynx and Natera discussed the cancer trials its Signatera test is being used in.
Three new studies have found that the presence of B cells in tertiary lymphoid structures in tumors is associated with a favorable response to immunotherapy.
Among the firms presenting, drugmakers, speciality biotechs, and genetic testing firms provided an update on their precision oncology development programs.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.
The finding suggests that African-American patients may be more likely to respond to treatment with poly ADP ribose polymerase (PARP) inhibitors.
With the participation of five cancer centers and clinics, Taproot is hoping to build a national, prospective data registry that is much needed but has been difficult to advance to date.
The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.